Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren

Alice Stanton, Chris Jensen, Juerg Nussberger, Eoin OBrien

Abstract—Inhibition of the first and rate-limiting step of the renin-angiotensin system has long been an elusive therapeutic goal. Aliskiren, the first known representative of a new class of completely nonpeptide, orally active, renin inhibitors, has been shown to inhibit the production of angiotensin I and II in healthy volunteers and to reduce blood pressure (BP) in sodium-depleted marmosets. The aim of this randomized, double-blind, active comparator trial study was to assess the BP-lowering efficacy and safety of aliskiren. Two hundred twenty-six patients, 21 to 70 years of age, with mild to moderate hypertension, were randomly assigned to receive 37.5 mg, 75 mg, 150 mg, or 300 mg aliskiren or 100 mg losartan daily for 4 weeks. Dose-dependent reductions in daytime ambulatory systolic blood pressure (mean change, mm Hg [SD of change]; −0.4 [11.7], −5.3 [11.3], −8.0 [11.0], and −11.0 [11.0], P=0.0002) and in plasma renin activity (median change % [interquartile range]; −55 [−64, −11], −60 [−82, −46], −77 [−86, −72], and −83 [−92, −71], P=0.0008) were observed with 37.5, 75, 150, and 300 mg aliskiren. The change in daytime systolic blood pressure with 100 mg losartan (−10.9 [13.8]) was not significantly different from the changes seen with 75, 150, and 300 mg aliskiren. Aliskiren was well tolerated at all doses studied. This study demonstrates that aliskiren, through inhibition of renin, is an effective and safe orally active BP-lowering agent. Whether renin inhibition results in protection from heart attack, stroke, and nephropathy, similar to angiotensin-converting enzyme inhibition and angiotensin receptor blockade, needs to be researched. (Hypertension. 2003;42:1137-1143.)

Key Words: renin ■ blood pressure ■ hypertension, essential ■ blood pressure monitoring, ambulatory ■ receptors, angiotensin ■ losartan

The renin-angiotensin system (RAS) has well-established roles in both blood pressure (BP) regulation and atherogenesis.1,2 Recent clinical trial evidence suggests that blockade of the RAS by angiotensin-converting enzyme inhibition or by angiotensin receptor blockade may influence large-vessel atherosclerosis and cardiovascular morbidity and mortality independent of BP lowering.3,4 As renin catalyzes the first and rate-limiting step of the system and has high specificity for angiotensinogen, blockade of the production of angiotensin (Ang) II by direct inhibition of renin has long been a therapeutic goal. Indeed, intravenous administration of the early renin inhibitors, such as enalkiren and remikiren, did reduce angiotensin levels and lower BP without any important adverse effects.5–8 However, to date, due to relatively low potency, poor oral bioavailability (<1%), short durations of action, and high costs of synthesis, none of these peptide and peptidomimetic inhibitors has made it to the end of clinical trials.9

Aliskiren, an octanamide, is the first known representative of a new class of completely nonpeptide, low-molecular-weight, orally active transition-state renin inhibitors.10 Designed through the use of molecular modeling techniques, it is a potent and specific in vitro inhibitor of human renin (IC50 in the low nanomolar range), with a plasma half-life of ≈24 hours.10 Aliskiren has good water solubility and low lipophilicity and is resistant to biodegradation by peptidases in the intestine, blood circulation, and the liver.10 When administered orally to sodium-depleted marmosets, it caused significant and sustained reductions in arterial blood pressure (unpublished data). In single-dose and multiple-dose tolerability studies in healthy normotensive male volunteers, oral doses up to 640 mg daily for 8 days were well tolerated and did not result in any significant toxicity.11 Micromolar plasma concentrations were achieved, and aliskiren was shown to cause a dose-dependent decrease in plasma renin activity (PRA), to effectively block the formation of both Ang I and Ang II, and to decrease plasma and urine aldosterone levels.11

In this study, we studied for the first time the efficacy, safety, and tolerability of 4 weeks of treatment with 37.5, 75, 150 and 300 mg aliskiren in healthy individuals with mild to moderate hypertension. We compared the effects of these various doses of aliskiren with the effects of 100 mg losartan.
once daily and also determined trough plasma concentrations of aliskiren and PRA at baseline and during treatment.

Methods

Participants
The study cohort consisted of men and women, 21 to 70 years of age, with off-treatment average daytime ambulatory systolic BP \( \geq 140 \) mm Hg, recruited from 5 hospital outpatient clinics in Ireland. Individuals were not eligible if they were unable to withdraw from current antihypertensive medications or if they had secondary hypertension, malignant hypertension, diabetes mellitus, coronary artery disease, or any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of aliskiren. All subjects gave written informed consent. The Irish Medicines Board and the appropriate local research ethics committees approved the study protocol, and the research was carried out in accordance with the Declaration of Helsinki (1996) of the World Medical Association.

Study Design
This was a double-blind, active comparator, randomized, parallel-group study. After a 1- to 3-week washout period, a screening 24-hour ambulatory blood pressure monitoring (ABPM) was performed to ensure that off-treatment average daytime ambulatory systolic BP was \( \geq 140 \) mm Hg. Patients remained off antihypertensive medication for a further week, after which a baseline ABPM was recorded. Patients, stratified by center and by previous antihypertensive therapy, were then randomly allocated to 1 of 5 treatment groups: 37.5 mg, 75 mg, 150 mg, or 300 mg aliskiren or 100 mg losartan. All patients were asked to take the encapsulated study medication, once daily, 30 minutes before eating breakfast. After 4 weeks of treatment, a third (end-of-treatment) ABPM was performed. All study personnel and participants remained blinded to treatment assignment for the duration of the study.

The screening assessment included a complete medical history, physical examination, clinic BP measurement, safety laboratory tests (blood hematology, blood chemistry and urinalysis), and electrocardiography. During each follow-up visit, adverse events, concurrent medication, and compliance with study medication were recorded, in addition to clinic BP measurement, safety laboratory tests, and electrocardiography. To determine trough aliskiren levels and PRA, additional venous blood samples were drawn from the patients while seated, at baseline, and 24 hours after the last dose of randomized study treatment. The plasma was separated and stored at \(-30^\circ C\).

Clinic Blood Pressure and Heart Rate Measurement
Sitting and standing clinic BP and heart rate were measured from the right arm, with the use of a regularly calibrated validated automated sphygmomanometer (Omron HEM-705CP),\(^{12}\) in accordance with the recommendations of the British Hypertension Society.\(^{13}\)

Ambulatory BP Monitoring
Ambulatory measurements were made every half-hour throughout the 24-hour period with the use of Spacelabs 90207 monitors.\(^{14}\) All data were transferred into a specialized software package (DABL), allowing calculation of mean daytime (9 AM and 9 PM) and nighttime (1 and 6 AM) systolic and diastolic blood pressures and heart rates.\(^{15,16}\) Ambulatory BP monitoring was regarded as satisfactory if there were at least 14 daytime readings and 6 nighttime readings.

Aliskiren Levels and PRA
Aliskiren was measured in 2.5 \( \mu L \) plasma by direct radioimmunoassay.\(^{11,17}\) PRA was measured by trapping of generated Ang I by antibodies and by subsequent radioimmunoassay.\(^{18}\)

Statistical Methods
All data analyses were carried out with the use of SAS software (SAS Institute Inc). Analyses concerning tolerability and safety were conducted on the safety population (n=226, all patients who received at least 1 dose of study treatment). Analyses concerning drug efficacy were performed on the intention-to-treat population (n=197, patients of the safety population with valid ABPMs at baseline and at end-of-treatment). Assuming a common standard deviation of 12.5 mm Hg for the change in baseline to end-of-treatment daytime ambulatory systolic BP, a significance level of 0.05 (2-sided), and 40 evaluable patients per treatment group, this study had 80% power to detect 3 mm Hg differences in the primary efficacy parameter, daytime ambulatory systolic BP, between the four aliskiren treatment groups.

ANCOVA was used to test the null hypothesis of no difference between each of the four aliskiren dose groups and to compare the individual doses of aliskiren versus 100 mg losartan. The ANCOVA model included the following factors and covariates: treatment group, center, previous hypertensive therapy (yes/no), and baseline value of DASBP. Pairwise comparisons of the responses to the different aliskiren doses and to losartan were conducted with the use of Scheffe’s method for multiple comparisons.

Results

Participants
Of the 345 patients recruited to this study, 226 satisfied all inclusion criteria and were randomly assigned to study treatment. Fourteen patients did not complete the study as planned, and a further 15 patients had invalid ABPMs either at baseline or at end-of-treatment (Figure 1). Baseline characteristics of the remaining 197 patients are shown in Table 1.

The distributions of gender, age, body mass index, lifestyle habits, and cardiovascular risk factors were similar across the 5 treatment groups. Baseline ambulatory BP levels and the proportions of patients in the 5 groups who had previously been exposed to antihypertensive drugs were also similar.

Drug Effects on BP
A clear dose-dependent decrease in the primary end point, the change in daytime ambulatory systolic BP, was observed with increasing aliskiren doses (ANCOVA treatment effect, \( P=0.0002 \)). Figure 2 illustrates that although there was practically no change in daytime ambulatory systolic BP with 37.5 mg aliskiren, a significant decrease was observed for 75 mg of aliskiren, with further reductions in pressure for doses of 150 and 300 mg aliskiren. Pairwise group comparisons showed significant differences between the lowest aliskiren dose group (aliskiren 37.5 mg) and the two highest dose groups; the 95% confidence intervals for the comparisons between 37.5 mg aliskiren with 150 mg aliskiren and 300 mg aliskiren were (0.6, 14.5) and (3.5, 17.5), respectively.

Losartan (100 mg) also significantly reduced daytime ambulatory systolic BP. The mean change from baseline to end-of-treatment in pressure in the group treated with 100 mg losartan was found to differ from that of the group treated with 37.5 mg aliskiren, a significant decrease was observed for 75 mg of aliskiren, with further reductions in pressure for doses of 150 and 300 mg aliskiren. Pairwise comparisons showed significant differences between the lowest aliskiren dose group (aliskiren 37.5 mg) and the two highest dose groups; the 95% confidence intervals for the comparisons between 37.5 mg aliskiren with 150 mg aliskiren and 300 mg aliskiren were (0.6, 14.5) and (3.5, 17.5), respectively.

Losartan (100 mg) also significantly reduced daytime ambulatory systolic BP. The mean change from baseline to end-of-treatment in pressure in the group treated with 100 mg losartan was found to differ from that of the group treated with 37.5 mg aliskiren—the 95% confidence interval for difference was (2.3, 18.6)—but not to differ significantly from the changes seen in the groups treated with 75, 150, and 300 mg aliskiren.

ANCOVA showed that whereas there was no difference in effects between the centers (\( P=0.79 \)), the pressure-lowering effects of aliskiren were greatest in patients with higher baseline values of daytime ambulatory systolic BP (\( P=0.007 \)) and in those patients who had not previously received antihypertensive therapy (\( P=0.043 \)).
Figure 3 clearly illustrates that BP lowering with aliskiren was dose-dependent throughout the whole 24 hours. Clinic systolic and diastolic BP, both in the sitting and in the standing positions, again clearly decreased with aliskiren in a dose-dependent manner, whereas heart rate was unaltered (Table 2). The decreases in clinic pressures seen with 100 mg losartan appeared similar to those of 150 mg and 300 mg aliskiren.

**Plasma Aliskiren Levels and Plasma Renin Activity**

Trough plasma concentrations of aliskiren increased with increasing doses of aliskiren (Table 3). Average baseline PRA was similar among the 5 treatment groups. After treatment with aliskiren, PRA decreased—the percentage reductions in PRA were 55%, 60%, 77%, and 83%, respectively \((P=0.0008)\) (Table 3). By contrast, PRA increased by 110% with 100 mg losartan daily. Further exploratory analyses suggested that the obtained on-treatment PRA remained directly related to baseline PRA (Figure 4), and Figure 5 illustrates that treatment with 300 mg aliskiren and with 100 mg losartan resulted in greater reductions in daytime systolic pressures in patients with higher baseline PRA levels.

**Compliance, Safety, and Adverse Effects**

Compliance, assessed from counts of returned capsules, averaged >95% across all treatment groups. Dosages up to 300 mg of aliskiren were well tolerated. Of the 226 patients in the safety population, 62 patients (27%) had a total of 108 adverse events. The numbers of patients in each of the groups treated with 37.5 mg, 75 mg, 150 mg, and 300 mg aliskiren

---

**TABLE 1. Baseline Demographic and Clinical Characteristics of the 197 Treated Patients**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Aliskiren 37.5 mg (n=39)</th>
<th>Aliskiren 75 mg (n=41)</th>
<th>Aliskiren 150 mg (n=41)</th>
<th>Aliskiren 300 mg (n=40)</th>
<th>Losartan 100 mg (n=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, M/F</td>
<td>27/12</td>
<td>30/11</td>
<td>27/14</td>
<td>23/17</td>
<td>23/13</td>
</tr>
<tr>
<td>Age, y</td>
<td>50.9±10.1</td>
<td>50.7±10.9</td>
<td>52.0±9.3</td>
<td>51.8±10.5</td>
<td>55.9±8.9</td>
</tr>
<tr>
<td>Height, cm</td>
<td>169.6±11.9</td>
<td>169±11.2</td>
<td>172±10.4</td>
<td>169.6±10.6</td>
<td>168.8±8.5</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>85.4±20.8</td>
<td>88.3±16.6</td>
<td>84.9±16.9</td>
<td>86.2±15.8</td>
<td>80.1±15.3</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>29.4±5.5</td>
<td>30.9±6.0</td>
<td>28.5±4.2</td>
<td>29.9±4.4</td>
<td>28.0±4.5</td>
</tr>
<tr>
<td>Smoking habit, smoker/ex/never</td>
<td>7/14/18</td>
<td>5/16/20</td>
<td>4/16/21</td>
<td>8/12/20</td>
<td>6/13/17</td>
</tr>
<tr>
<td>Alcohol habit, drinker/nondrinker</td>
<td>28/11</td>
<td>33/8</td>
<td>29/12</td>
<td>25/15</td>
<td>26/10</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.6±1.0</td>
<td>5.7±1.0</td>
<td>5.8±1.0</td>
<td>6.0±1.1</td>
<td>5.8±0.7</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>2.0±2.1</td>
<td>2.1±1.7</td>
<td>2.0±1.1</td>
<td>2.2±1.7</td>
<td>1.9±1.7</td>
</tr>
<tr>
<td>Creatinine, μmol/L</td>
<td>96±15</td>
<td>98±14</td>
<td>95±14</td>
<td>95±13</td>
<td>94±13</td>
</tr>
<tr>
<td>Daytime ambulatory SBP</td>
<td>153.8±13.1</td>
<td>153.9±11.0</td>
<td>156.2±10.5</td>
<td>152.6±9.7</td>
<td>152.6±10.5</td>
</tr>
<tr>
<td>Daytime ambulatory DBP</td>
<td>93.3±12.3</td>
<td>94.5±9.9</td>
<td>96.5±8.4</td>
<td>93.5±8.9</td>
<td>91.1±9.0</td>
</tr>
<tr>
<td>Nighttime ambulatory SBP</td>
<td>130.1±17.9</td>
<td>131.9±16.4</td>
<td>132.6±14.9</td>
<td>132.4±13.6</td>
<td>135.1±12.9</td>
</tr>
<tr>
<td>Nighttime ambulatory DBP</td>
<td>74.5±11.4</td>
<td>77.6±11.7</td>
<td>78.0±11.5</td>
<td>77.6±9.4</td>
<td>78.6±12.1</td>
</tr>
</tbody>
</table>

Previous antihypertensive therapy, yes/no

Data are expressed as mean±SD or proportions as appropriate.

There were no significant differences in demographic and clinical characteristics among the 5 treatment groups at baseline.
and in the group treated with 100 mg losartan who had adverse events were 10 (22%), 16 (35%), 11 (25%), 11 (23%), and 14 (32%) respectively. The most common adverse events were fatigue or weakness, gastrointestinal disorders, or headaches. No accumulation of adverse events was observed in any of the system organ classes and treatment groups. There was no increase in the number of adverse events when increasing the dose of aliskiren. In general, the incidence of each adverse event was very low.

Three patients had serious adverse events during the active treatment phase. One patient in the group treated with 300 mg aliskiren had chest tightness and electrocardiographic ischemic changes, and another patient in the same treatment group collapsed and was found to be hypotensive. Both patients recovered. A losartan-treated patient died as a result of a ruptured aneurysm of the left common iliac artery. A further 8 patients had adverse events resulting in withdrawal from the study. Of the patients withdrawn from the study because of a serious adverse event or an adverse event, 1 of 2, 3 of 3, 0 of 0, 2 of 3, and 1 of 3 in the 37.5 mg, 75 mg, 150 mg, and 300 mg aliskiren-treated and losartan-treated groups, respectively, had events that were considered by the investigator to be possibly or probably related to the study drug.

The clinical laboratory values remained normal in the majority of patients throughout the study. Shifts from normal values at baseline to abnormal values at the end of the study in some patients in the different treatment groups did not reveal a pattern indicating that any of the study drugs administered might have a marked influence on any of the laboratory parameters. Physical examination findings were normal in the majority of patients at screening and the end of the study. This also applied to the ECG tracings recorded on each of the 5 visits.

### TABLE 2. Baseline Clinic Blood Pressures and Heart Rates, and Changes From Baseline With Study Treatment

<table>
<thead>
<tr>
<th>Hemodynamic Parameter</th>
<th>Aliskiren 37.5 mg</th>
<th>Aliskiren 75 mg</th>
<th>Aliskiren 150 mg</th>
<th>Aliskiren 300 mg</th>
<th>Losartan 100 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitting SBP</td>
<td>156.8 ± 18.9</td>
<td>158.2 ± 19.4</td>
<td>159.5 ± 18.5</td>
<td>157.6 ± 16.8</td>
<td>159.0 ± 15.5</td>
</tr>
<tr>
<td>Change</td>
<td>-4.3 ± 17.8</td>
<td>-4.1 ± 16.9</td>
<td>-10.0 ± 17.0</td>
<td>-11.8 ± 14.9</td>
<td>-11.4 ± 19.2</td>
</tr>
<tr>
<td>Sitting DBP</td>
<td>92.7 ± 11.4</td>
<td>93.4 ± 11.4</td>
<td>93.3 ± 9.9</td>
<td>94.1 ± 11.1</td>
<td>95.0 ± 8.1</td>
</tr>
<tr>
<td>Change</td>
<td>-1.9 ± 10.5</td>
<td>-0.2 ± 12.4</td>
<td>-2.2 ± 10.0</td>
<td>-5.7 ± 11.0</td>
<td>-5.5 ± 10.7</td>
</tr>
<tr>
<td>Sitting HR</td>
<td>71.1 ± 11.0</td>
<td>76.7 ± 13.9</td>
<td>74.0 ± 15.3</td>
<td>73.9 ± 10.7</td>
<td>72.9 ± 11.4</td>
</tr>
<tr>
<td>Change</td>
<td>0.3 ± 9.2</td>
<td>-3.9 ± 9.1</td>
<td>-2.4 ± 11.6</td>
<td>1.5 ± 9.9</td>
<td>-2.0 ± 10.1</td>
</tr>
<tr>
<td>Standing SBP</td>
<td>158.5 ± 18.4</td>
<td>158.8 ± 23.4</td>
<td>159.1 ± 19.5</td>
<td>161.6 ± 18.7</td>
<td>158.8 ± 18.5</td>
</tr>
<tr>
<td>Change</td>
<td>-4.3 ± 15.7</td>
<td>-4.7 ± 12.0</td>
<td>-10.5 ± 18.3</td>
<td>-14.1 ± 14.4</td>
<td>-9.4 ± 21.9</td>
</tr>
<tr>
<td>Standing DBP</td>
<td>97.2 ± 13.0</td>
<td>97.0 ± 13.9</td>
<td>97.0 ± 10.7</td>
<td>100.5 ± 11.1</td>
<td>98.8 ± 11.0</td>
</tr>
<tr>
<td>Change</td>
<td>-1.9 ± 12.0</td>
<td>-0.6 ± 10.7</td>
<td>-3.5 ± 10.5</td>
<td>-8.2 ± 12.0</td>
<td>-5.7 ± 12.0</td>
</tr>
<tr>
<td>Standing HR</td>
<td>72.7 ± 10.0</td>
<td>79.9 ± 15.1</td>
<td>77.1 ± 14.5</td>
<td>77.6 ± 12.0</td>
<td>74.6 ± 11.3</td>
</tr>
<tr>
<td>Change</td>
<td>2.5 ± 11.3</td>
<td>-3.3 ± 10.1</td>
<td>-0.6 ± 10.7</td>
<td>2.6 ± 9.4</td>
<td>-0.4 ± 9.9</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD.
TABLE 3. Trough Plasma Aliskiren Levels and Trough Plasma Renin Activity at Baseline and After 4 Weeks of Treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Aliskiren 37.5 mg</th>
<th>Aliskiren 75 mg</th>
<th>Aliskiren 150 mg</th>
<th>Aliskiren 300 mg</th>
<th>Losartan 100 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trough Plasma Aliskiren, ng/mL</td>
<td>2.6 (1.6, 3.4)</td>
<td>4.2 (3.2, 6.4)</td>
<td>9.9 (6.5, 14.0)</td>
<td>30.0 (17.5, 50.0)</td>
<td>...</td>
</tr>
<tr>
<td>PRA at baseline, ng/mL/h</td>
<td>0.56 (0.25, 0.97)</td>
<td>0.85 (0.38, 1.13)</td>
<td>0.70 (0.42, 1.30)</td>
<td>0.80 (0.48, 1.30)</td>
<td>0.71 (0.36, 1.23)</td>
</tr>
<tr>
<td>PRA on treatment, ng/mL/h</td>
<td>0.27 (0.11, 0.61)</td>
<td>0.25 (0.12, 0.49)</td>
<td>0.14 (0.07, 0.32)</td>
<td>0.16 (0.06, 0.31)</td>
<td>1.65 (0.69, 2.90)</td>
</tr>
<tr>
<td>PRA percentage change, %</td>
<td>−55 (−64, −11)</td>
<td>−60 (−82, −46)</td>
<td>−77 (−86, −72)</td>
<td>−83 (−92, −71)</td>
<td>110 (8, 260)*</td>
</tr>
</tbody>
</table>

Data expressed as median (interquartile range). All available data are shown: plasma aliskiren, baseline PRA, on-treatment PRA, and % change in PRA values were available for 192, 194, 191, and 187 subjects, respectively.

Changes in plasma renin activity did vary significantly with aliskiren dose (ANOVA P = 0.0008).

*Statistically significant difference from response to aliskiren 37.5.

Discussion

The results of our current study clearly demonstrate, for the first time, that oral aliskiren, once daily, effectively reduces BP in a dose-dependent manner. Previous data on circulating Ang II concentrations in normal volunteers suggested that 150 mg aliskiren would provide equipotent RAS inhibition to 20 mg enalapril. However, a recent meta-analysis of 43 published randomized controlled trials of losartan, valsartan, irbesartan, and candesartan has demonstrated comparable antihypertensive efficacy within the class. Furthermore, participants randomly assigned to losartan-based antihypertensive treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial had 11% fewer cardiovascular deaths and 25% fewer strokes than those randomly assigned to atenolol-based treatment.

As expected, the antihypertensive effects of both the renin inhibitor and the angiotensin receptor blocker appeared somewhat greater in patients in whom the RAS was activated, as reflected by higher baseline PRA levels. Interestingly, although the achieved on-treatment PRA levels and the percentage inhibition of PRA with 150 mg and 300 mg aliskiren did not appear to substantially differ, there was no appearance of a plateau in the dose-response curve for BP effects. Hence, higher doses of aliskiren may result in further lowering of pressures. Furthermore, on-treatment trough PRA levels may not fully reflect the extent of inhibition throughout the whole 24 hours. Alternatively, local generation of Ang II, contributing to BP elevation, may only be effectively inhibited at higher aliskiren doses, with achievement of greater tissue penetration.

We used daytime ambulatory systolic BP as the primary efficacy end point because of the overwhelming evidence of the importance of systolic pressure as a prognostic indicator, the enhanced reproducibility of ambulatory BP parameters over clinic BP measures, and the additional information gained concerning the extent and duration of BP lowering in real-life conditions. This study was an active comparator-controlled trial rather than a placebo-controlled trial. Hence, it was not possible to calculate placebo-corrected BP reductions with each treatment. However, as ambulatory pressures demonstrate little placebo effect, no important error was introduced by the use of absolute BP reductions. The performance of separate screening ABPMs and baseline ABPMs facilitated exclusion of patients with white-coat hypertension and avoidance of regression to the mean.

The other principal finding of this study was that aliskiren was well tolerated across all doses tested. This confirms previous knowledge concerning the safety of aliskiren derived from smaller studies in healthy normotensive volunteers. In contrast to ACE, which acts on bradykinin in addition to Ang I, renin is highly selective for a single naturally occurring substrate, angiotensinogen. Although the increased levels of bradykinin and substance P that occur with ACE inhibition may contribute to BP lowering, they are also held responsible for side effects such as cough and angioedema. Given the selectivity of both aliskiren for renin and renin for angiotensinogen, it was not surprising to observe that aliskiren appears to have a side effect profile similar to that of placebo.

In addition to differences in side effect profile, the therapeutic effects of renin inhibitors may differ from those produced by blockade at other levels in the RAS. Alternative pathways to renin cleavage of angiotensinogen are not thought to be of any great physiological importance, whereas a substantial proportion of tissue Ang II is generated by non-ACE pathways. Hence, it has been proposed that more effective blockade of tissue Ang II formation may occur with renin inhibition than with ACE inhibition. Further differences between renin inhibition, ACE inhibition, and angiotensin receptor blockade could arise from disparate effects on circulating and tissue levels of bioactive Ang peptides and different patterns of stimulation of the various receptor subtypes.

Perspectives

The results of this study show that aliskiren is a safe, orally active renin inhibitor that lowers BP. Despite the wealth of evidence that reduction of BP provides important protection, undertreatment of hypertension is a worldwide problem. Hence, an agent that effectively and specifically blocks the RAS, with a novel mechanism of action, with few side effects, and with a half-life long enough to allow once daily dosage, is to be welcomed. Should further larger trials of a longer duration confirm sustained BP lowering, a placebo-like side effect profile,
and similar or superior effects on intermediate end points, such as left ventricular hypertrophy, carotid intima media thickness, and proteinuria, to those of the established RAS antagonists, renin inhibitors may soon be widely prescribed for essential hypertension. Given the success of ACE inhibitors and angiotensin receptor blockers in reducing morbidity and mortality rates among patients with diabetes mellitus, heart failure, nephropathy, and atherosclerosis, renin inhibitors also have the potential to be beneficial in the same disease states.
Acknowledgments

This renin inhibitor trial was sponsored by Speedel Pharma AG, Basel, Switzerland. Data management and statistical analyses were performed by Quintiles GmbH, Frankfurt, Germany. We thank the following colleagues for recruitment of the participants: John Barton, Portiuncula Hospital, Galway; Brendan Meeney, Limerick Regional Hospital, Limerick; David Mulcahy, Adelaide and Meath Hospital, Dublin; and Michael Murphy, Cork University Hospital, Cork.

References

Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
Alice Stanton, Chris Jensen, Juerg Nussberger and Eoin O'Brien

Hypertension. 2003;42:1137-1143; originally published online November 3, 2003;
doi: 10.1161/01.HYP.0000101688.17370.87
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/42/6/1137

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/